Treating advanced lung cancer with interstitial lung disease
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests two treatment strategies for people with advanced non-small cell lung cancer who also have interstitial lung disease (a condition causing lung scarring). It aims to find a safe and effective treatment option for this specific group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (stage IIIB/IV) non-small cell lung cancer that cannot be treated with radiation
- You have a diagnosis of interstitial lung disease (any type for first-time treatment, or certain types and severity for second-line treatment)
- You are 18 years or older and able to give written consent
- You have not had prior treatment for advanced disease (for the first-line part) or have had only one prior platinum-based chemotherapy (for the second-line part)
- Your organs and blood counts are within required limits (like kidney and liver function)
- You are willing to use highly effective contraception during and for 7 months after treatment (if applicable)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a type of chemotherapy called platinum-based chemo to an immunotherapy drug called tislelizumab helps people with advanced non-small cell lung cancer that has spread and has high PD-L1. The trial aims to see if this combination works better than immunotherapy alone in people with larger tumors.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This trial tests a new way of giving radiation (in high and low doses) together with chemotherapy and immunotherapy to treat advanced non-small cell lung cancer. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of an immunotherapy drug (sintilimab) with chemotherapy to shrink advanced lung cancer that cannot be removed with surgery. The goal is to see if the cancer becomes operable after treatment and to improve outcomes.
This trial tests how well chemotherapy works for people with stage IV non-small cell lung cancer that has spread. It is for those who have already tried at least one prior treatment and are healthy enough for more therapy.
This trial tests a pill form of chemotherapy (oral paclitaxel) combined with an immunotherapy drug to keep advanced lung cancer from growing after initial treatment. It may help patients whose cancer was controlled with first-line therapy.
Hear when a new Non Small Cell Lung Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.